All News

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

Raj Indupuri, CEO, eClinical Solutions,pharma’s biggest AI adoption hurdles lie in scaling beyond pilots, ensuring data security, and building user trust within a regulated environment.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s plan to submit its oral GLP-1 candidate for FDA priority review, the departure of senior FDA official George Tidmarsh, and growing global venture capital investment in biopharma innovation.

The personal care corporation will add Tylenol to its portfolio, along with the rest of Kenvue’s brands.

Pfizer's lawsuits come after Novo Nordisk proposed an unsolicited acquisition proposal to Metsera.

There are conflicting reports as to the cause, although it appears to be related to a lawsuit that alleges inappropriate conduct.

Eli Lilly invests $3 billion in a new European manufacturing facility, enhancing production capacity and creating jobs while ensuring faster access to innovative medicines.

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

Raj Indupuri, CEO, eClinical Solutions, touches on AI's transformation of pharma by streamlining clinical development processes, automating data management, accelerating cycle times, and improving decision-making across trials.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s unsolicited proposal to acquire Metsera, renewed legal action against Tylenol’s manufacturer following statements from Robert F. Kennedy Jr., and AbbVie’s stronger 2025 profit outlook driven by immunology demand.

The move could signal a potential partnership between Eli Lilly and TrumpRx.

Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.

Join us for a premium webinar on November 4, 2025!

The change was driven by strong sales of Skyrizi and Rinvoq, and showcases robust growth and innovation in its portfolio.

Five key takeaways from the Future Investment Initiative panel on the Gulf region’s growing role in global VC.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover Thermo Fisher’s $8 billion agreement to acquire Clario Holdings, Eli Lilly’s partnership with Walmart to launch retail pickup for its direct-to-consumer Zepbound program, and the FDA’s new draft guidance aimed at streamlining biosimilar development.

Texas filed its lawsuit just days before Kennedy made his remarks.

The company will no longer be spinning CSL Seqirus next June.

Novo Nordisk proposes a $9 billion acquisition of Metsera, prompting responses from both Metsera and Pfizer amid ongoing merger discussions.

Eli Lilly invests $1.2 billion in Puerto Rico to enhance manufacturing capabilities, creating jobs and integrating advanced technologies for oral medicines.

Marcel Botha, CEO of 10XBeta, discusses FDA’s new pilot authorization program for abbreviated new drug applications (ANDA) and what impact it will have on manufacturing and the supply chain.

In today’s Pharmaceutical Executive Daily, we cover Eli Lilly’s partnership with NVIDIA to develop an AI supercomputer for drug discovery, a surge in biotech funding rounds and public offerings, and the FDA approval of Merck’s Winrevair for pulmonary arterial hypertension.

The agency says the new guidelines will simplify the requirements to bring biosimilars to market.

President Trump’s claims about $150 weight-loss medication are causing investors to question the importance of the contents of the current earnings reports.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

The acquisition aims to enhance drug development capabilities and accelerate clinical research innovation.

Zepbound will be offered as part of the LillyDirect program and will be available to patients for pick-up in over 4600 Walmart Pharmacies nationwide.